| SEC For | m 4 | | | | | | | | | | | | | | | | |
|---|----------|--|---|-------|--|--|-----------------|-----------|--|--------------------|---|--|---|---|--|--|--|
| FORM 4 UNITED S | | | |) STA | TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | | OMB APPROVAL | | |
| Section 16. Form 4 or Form 5 obligations may continue. See | | | | | | A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | | | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | | |
| 1. Name and Address of Reporting Person [*] Wahl Bryan | | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>Tarsus Pharmaceuticals, Inc.</u> [TARS] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) | | | |
| (Last) (First) (Middle) C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/09/2022 | | | | | | | | General Counsel | | | | |
| (Street) IRVINE | (Street) | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | Line | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
| (City) | (S | tate) | (Zip) | | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | | Execution Date, | | | Code (Ins | Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5) | | | I Securities Form Beneficially (D) of | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | | Code V | Amoun | nount (A) or Pr | | Transact (Instr. 3 a | ion(s) | | (| |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security | | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | | ransacti ode (Ins | on of str. De Ac (A Di of | 5. Number of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | Owners Form: Direct (I or Indire (I) (Instr | Beneficial Ownership ct (Instr. 4) | |
| | | | | c | ode V | (A | 5) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | |
| Stock Option (right to buy) | \$19.59 | 03/09/2022 | | | A | 65 | 5,312 | | (1) | 03/08/2032 | Common Stock | 65,312 | \$0 | 65,312 | D | | |
| Restricted Stock Units | (2) | 03/09/2022 | | | A | 19 | 9,160 | | (3) | (3) | Common Stock | 19,160 | \$0 | 19,160 | D | | |
| Restricted Stock Units | (2) | 03/09/2022 | | | Α | 34 | 4,171 | | (4) | (4) | Common Stock | 34,171 | \$0 | 34,171 | D | | |

Explanation of Responses:

1. 25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

4. 30% of the RSUs will vest on November 29, 2022 and 70% of the RSUs will vest on November 29, 2023 subject to the Reporting Person's continuous service.

Remarks:

<u>/s/ Leonard M. Greenstein,</u> <u>Attorney-in-Fact</u>

** Signature of Reporting Person

03/11/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.